Literature DB >> 11148711

Behçet disease.

H Yazici1, S Yurdakul, V Hamuryudan.   

Abstract

Central nervous system involvement in Behçet disease (BD) may be either parenchymal or nonparenchymal. Abnormal cerebrospinal fluid findings and parenchymal involvement are associated with a poorer prognosis. A self-antigenic role for HLA B51 has been postulated in the pathogenesis of BD. The sibling occurrence rate is 3.6%. Familial aggregation may be more pronounced among pediatric cases compared with adult cases. The importance of inherited coagulation abnormalities in the pathogenesis of BD is not clear. Vasculitis of the vasa vasorum seems to be the major site of pathology in large vessel disease. Even among experts, no consensus exists regarding the optimal approach to treatment. Low-dose thalidomide is effective for the mucocutaneous lesions, but polyneuropathy complicates its prolonged use. Neurologic side effects of cyclosporine A should preclude its use in patients with central nervous system involvement except in unusual circumstances. The heightened inflammatory response of BD patients to simple trauma may lead to postoperative complications, but should not be regarded as a contraindication to surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11148711     DOI: 10.1097/00002281-200101000-00004

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  21 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 2.  Immunologically mediated dementias.

Authors:  Michael H Rosenbloom; Sallie Smith; Gulden Akdal; Michael D Geschwind
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

3.  Venous vessel wall thickness in lower extremity is increased in male patients with Behcet's disease.

Authors:  Fatma Alibaz-Oner; Rabia Ergelen; Aydan Mutis; Zeynep Erturk; Ruslan Asadov; Gonca Mumcu; Tulin Ergun; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2019-02-13       Impact factor: 2.980

4.  Prevalence and clinical aspects of Behcet's disease in the north of Israel.

Authors:  Ilan Krause; Anna Yankevich; Abigail Fraser; Itzhak Rosner; Reuven Mader; Devy Zisman; Nina Boulman; Michael Rozenbaum; Abraham Weinberger
Journal:  Clin Rheumatol       Date:  2006-08-01       Impact factor: 2.980

5.  A 30-year-old female Behçet's disease patient with recurrent pleural and pericardial effusion and elevated adenosine deaminase levels: case report.

Authors:  Joon Young Choi; Sung-Hwan Kim; Seung-Ki Kwok; Jung Im Jung; Kyo-Young Lee; Tae-Jung Kim; Ji Young Kang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 6.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

Review 7.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

8.  DD genotype of ACE gene I/D polymorphism is associated with Behcet disease in a Turkish population.

Authors:  Serbülent Yigit; Sengül Tural; Aydin Rüstemoglu; Ahmet Inanir; Ulker Gul; Goknur Kalkan; Songul Akkanet; Nevin Karakuş; Omer Ateş
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

9.  Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with behçet and central nervous disease.

Authors:  Concepción M Nuñez-Sotelo; Luis A Gutiérrez-Gonzalez; Martín A Rodriguez
Journal:  Maedica (Buchar)       Date:  2012-12

10.  The clinical feature of Behçet's disease in Northeastern China.

Authors:  Yingbin Shang; Shixin Han; Jiuhong Li; Qiushi Ren; Fangji Song; Hongduo Chen
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.